Does your urinalysis system pass the acid test?

Only one system screens for ascorbic acid — the Behring Rapimat II/T Urinalysis System

Millions of Americans take ascorbic acid (vitamin C), which can result in decreased or false negative results for urinary blood, glucose, bilirubin and nitrite. Only the Behring Rapimat II/T Urinalysis System passes the acid test and detects ascorbic acid interference. See for yourself; call for a demonstration.

Advanced technology enhances accuracy and convenience
- Heated LE pad improves sensitivity and specificity, reliably eliminating unnecessary microscopics and cultures
- Color compensation pad improves accuracy by adjusting for urine color variation
- Positive results printed in red for easy identification
- “Hands-off,” sanitary disposal of test strips

Cost-saving — the acid test in today’s lab
The challenge for any urinalysis system today is to reduce labor and supply costs. Call us today and see how much the Rapimat II/T Urinalysis System can save your lab.

Rapimat II/T Urinalysis System
Performance that passes the acid test
The Salon du Laboratoire is working towards improving life. It is a technological platform open to clinical biology, biotechnology, reagents and all the industries involved in the laboratory world. The exhibition is a select trade event and a showcase for quality, technology and production. In order to fulfil the demands of this constantly developing field, the event is now associated with 13 scientific societies. Scientific symposia and conferences will be held throughout the five days of the show. The Salon du Laboratoire is an international event. This year, it will bring together more than 4,000 congress participants and over 1,000 companies.

For further information, contact SEPIC-SALON DU LABORATOIRE Tel. 33 (1) 40 39 16 82 Fax 33 (1) 42 36 20 60
WAIT AROUND TIME OR TURNAROUND TIME?

How often are you locked out of your system? On the AIA-1200* and AIA-600, you can load patient samples at any time. Select a complete profile or a single analyte for each sample. And walk away...Come back at any time to add samples, make STAT requests or review data...The AIA-1200 and AIA-600 are always ready to respond. The result: over 1000% improvement in turnaround time.¹ For more information, contact Tosoh Medics today.

¹Based on studies at major medical centers. Details available upon request. *For investigational use only.
Introducing!!!

2 NEW TITLES FROM AACC PRESS

Methods for Clinical Laboratory Measurement of Lipid and Lipoprotein Risk Factors
Edited by Nader Rifai and G. Russell Warnick

Guidelines for the clinical management of high blood cholesterol have been developed and are being widely adopted by clinicians. If individuals are to be classified correctly and the response to therapy is to be monitored with confidence, such levels have to be sufficiently accurate. However, some doubts have arisen regarding the performance of some laboratories and a certain lack of public confidence in cholesterol measurement has been expressed.

Methods for Clinical Laboratory Measurement of Lipid and Lipoprotein Risk Factors provides the necessary clinical background, discusses the important questions of preanalytical variation, and then systematically deals with each of the more common lipid and apoprotein measurements. Standardization of measurement and the special case of desktop analyzers are carefully considered.

This volume is a mine of valuable information and will do much to ensure quality measurement, which should help to restore public confidence in lipid measurement. (160 pages)


Effects of Drugs on Clinical Laboratory Tests, 1991 Supplement
Edited by Donald S. Young

This supplement to the third edition of The Effects of Drugs on Clinical Laboratory Tests, comprises primarily the effects published in the literature in 1988 and 1989.

This supplement ensures that The Effects of Drugs on Clinical Laboratory Tests maintains the comprehensiveness essential to such a wide-ranging compilation. Effects covered under the time frame of the 1990 edition, but not documented until after publication, are also included in the supplement.

This supplement is organized in the same format as the 1990 edition of Effects of Drugs on Clinical Laboratory Tests. It contains approximately 6,000 drug-test interferences compiled from a search of literature since publication of the 1990 edition. (368 pages)

Members $40.  Non-Members $60.

To order by phone: Call AACC's Publications Department
1-800-892-1400/202-857-0717 or write:
AACC Press
2029 K Street, NW, 7th Floor, Washington, D.C. 20006 U.S.A.

Circle No. 305 on Reader Service Card
If you're in clinical chemistry, you should be in the AACC.

Medical technologist, chemist, pathologist, researcher, lab technician, sales representative, manufacturer, lab manager...if your profession touches the world of clinical chemistry, it's vital that you keep up with the constantly changing news and developments in the field. The AACC is here for you.

The American Association for Clinical Chemistry gives you a forum for the exchange of ideas and solutions...the sharing of problems...the updating of new and exciting developments...the meeting of new colleagues...and the building of crucial professional relationships.

Membership in the AACC can broaden and enhance your knowledge and understanding of the clinical chemistry field as well as facilitate making contacts that are critical to your career growth.

<table>
<thead>
<tr>
<th>Category of Membership</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ MEMBER $100 (Open to persons holding an earned baccalaureate or higher degree in science, medicine, or academic equivalent and engaged in professional activities commonly associated with clinical chemistry. Includes subscription of Clinical Chemistry.)</td>
</tr>
<tr>
<td>☐ AFFILIATE $50 (Open to persons with an interest in the clinical chemistry field who do not desire or qualify for other membership categories.)</td>
</tr>
<tr>
<td>☐ STUDENT ASSOCIATE $25 I certify I am enrolled fulltime at (school/city/state) and expect to graduate in (month and year). I am seeking the _______ degree.</td>
</tr>
</tbody>
</table>

Payment
☐ Check (payable in U.S. dollars to AACC.) Amount $________
☐ VISA #_______________ Exp. date ______
☐ Mastercard #_________ Exp. date ______
Signature ____________________________ Date ____________

I hereby certify that I am enrolled full-time at (school/city/state) and expect to graduate in (month and year). I am seeking the _______ degree.

Category of Membership

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEMBER $100</td>
<td>$100</td>
</tr>
<tr>
<td>AFFILIATE $50</td>
<td>$50</td>
</tr>
<tr>
<td>STUDENT ASSOCIATE $25</td>
<td>$25</td>
</tr>
</tbody>
</table>

Address

Name

Last: ________________ First: ________________ Middle Initial: ________________

Address: ____________________________________________

City/State/Zip: ____________________________

Daytime Phone: ____________________________

Job Title/Occupation: ______________________

Highest Degree: ________________ Major: ________________ Yr. Rec'd: ________________

School: ____________________________ City/State: ____________________________

Mail completed application and payment to: American Association for Clinical Chemistry, 2029 K Street, N.W., Washington, D.C. 20006 • 800-892-1400 • 202-857-0717 • FAX 202-887-5093

FOR OFFICE USE: Appl. # ______ Local Section ______
Mbr. Type ______ Appt. Source _______ Amt. Paid _______
Chk. # __________________________ Date ____________

Circle No. 304 on Reader Service Card
STUDENT PROGRAMS

Student Poster Contest

- Five cash awards
- Contestants must
  - be post-doctoral fellows, or undergraduate or graduate students, in clinical chemistry—and submit a letter verifying student status with their abstract
  - be the presenting author of an accepted abstract
  - submit only one poster as the principal presenting author (contestants may be listed as co-authors on other abstracts)
  - present the accepted abstract at both the student poster contest and at regularly scheduled poster sessions

Student Travel Grant

- Waiver of meeting registration fee, payment of $100 for expenses, and participation in two breakfast roundtables
- Contestants must
  - be post-doctoral fellows, or undergraduate or graduate students, in clinical chemistry—and submit a letter verifying student status with their application
  - be members of AACC
  - be an author of an accepted abstract
  - not have received the grant previously

APPLICATION INSTRUCTIONS

1. Follow the submission requirements listed on the abstract form.

2. Obtain a letter from your school advisor verifying your student status.

3. For the poster contest: 3. For the student travel grant:

   a. Write a cover letter to the Career Education Committee stating your wish to enter the poster contest.
   a. Write a cover letter to the Career Education Committee stating your request for a travel grant, and include your membership number.

   b. Make an additional copy of the abstract of which you are the presenting author.
   b. Make one copy of the abstract of which you are an author.

   c. Mail the copy of the abstract, your cover letter, and the letter verifying your student status, postmarked by Dec. 16, 1991, to:
   c. Mail the copy of the abstract, your cover letter, and the letter verifying your student status, postmarked by Dec. 16, 1991, to:

      Career Education Committee, Career Education Committee,
      Box A Box B
      AACC AACC
      2029 K St. NW, 7th floor 2029 K St. NW, 7th floor
      Washington, D.C. 20006 USA Washington, D.C. 20006 USA

4. If you are entering the student poster contest and applying for a travel grant, you must submit a separate application for each.

Questions? Call the AACC Education Office at 1-800-892-1400.
Circle No. 302 on Reader Service Card
1992 National Meeting—Call for Abstracts
American Association for Clinical Chemistry
July 19–23, Chicago, IL

READ ALL INSTRUCTIONS CAREFULLY
DEADLINE: ENVELOPES MUST BE CANCELLED BY AN APPROVED POSTAL CARRIER NO LATER THAN DECEMBER 16, 1991.

Abstract forms are included in the September issue of the Journal or can be obtained by contacting the AACC Meeting Department, 2029 K Street, NW, Suite 700, Washington, DC 20006, 800-892-1400/202-857-0717/TLX 251925 AACCUR

INSTRUCTIONS FOR PREPARATION

In order to be accepted, abstracts of papers that are to be presented at the AACC National Meeting must meet certain criteria and format. Each correctly submitted abstract will be subject to peer review and evaluated by identical criteria as to its relevance to clinical chemistry, clarity and content.

Failure to follow instructions for preparation and submission of abstracts will lead to rejection of an otherwise acceptable paper with no opportunity to resubmit.

1. Content of Abstracts

The information in each abstract must include and clearly state:

a. the objective of the study
b. sufficient information to demonstrate relevance to clinical chemistry
c. methodology (if pertinent)
d. results obtained
e. sufficient data to support conclusion
f. conclusions

The content must not be previously published.

Statements such as “results will be discussed” are not satisfactory and will be cause for rejection of the abstract.

NOTE: Relevant technical information cannot be withheld on the ground that such information is proprietary.

IF YOUR PAPER INVOLVES THE DEVELOPMENT OF A NEW ANALYTICAL METHOD OR PROCEDURE, YOU SHOULD INCLUDE IN THE ABSTRACT THE FOLLOWING INFORMATION:

a. Specimen.
b. Reagents and standards used. If chromatography is involved, state the source of the column packing.
c. Brief description of the methodology used.
d. Linearity data.
e. Precision data.
f. Comparison with a known, currently-accepted method if available.
g. Recovery data if extraction or prechromatography is used.
h. An interference study if a chromatographic procedure or immunoassay. The entire list of substances included in the interference study should not be stated in the abstract but must be given during the presentation at the meeting.

2. Abstract Form

Abstracts must be submitted on the official AACC Abstract Reproduction Form contained in the September issue of the AACC journal, Clinical Chemistry. Additional forms may be obtained from the AACC Meeting Department, 2029 K Street, NW, Suite 700, Washington, DC 20006 USA, 800-892-1400, 202-857-0717, TLX: 251925 AACCUR, FAX: 202-887-5093.

Abstracts will be photographically reproduced in Clinical Chemistry exactly as you submit them.

—DO NOT USE A DOT MATRIX PRINTER.
—Make sure the print is dark and clear
—Print must be in black ink
—When Preparing Abstracts on:
  • Normal Typewriter—use elite type at 12 characters per inch
  • Computer Typewriter—use elite type (10 point) at 12 characters per inch
  • Computer Laser Printers—use any style font with 10 point characters, print abstract on plain paper, measured to the inside perimeters of the blue box on the form; then cut and affix original to abstract form.

Do not erase. Any errors, misspellings, and/or deviations from good grammar that appear in the text will NOT be corrected before reproduction.

3. Title/Author/Affiliation

The title should be brief, clearly indicating the nature of the work. Words such as “new” and “novel” and other adjectives representing value judgments such as “improved methods” should be avoided unless they can clearly and objectively be described in the abstract itself. Minimize the use of subscripts, superscripts, and hyphenated words.

After the title, state the author(s) name(s); list first and underline the name of the presenting author. Next, the author(s) affiliation(s) should appear in parentheses (see sample abstract). Use abbreviations to save space and omit

NOTE: Sponsorship is no longer required for submission of an abstract.

4. Presenting Author

The name, address and phone number of the presenting author must be typed on the Abstract Reproduction Form, given first and underlined in the listing of authors in the abstract text. ALL correspondence concerning the abstract will be sent to the presenting author.

ABSTRACT PREPARATION:

Failure to comply with the following will lead to rejection prior to being submitted for review of an otherwise acceptable paper. Check box at left as each item is completed:

☐ 1. Topic Areas: Topic areas (listed on page 18A) must be indicated. The Contributed Papers Committee reserves the right to determine the final topic assignment.

☐ 2. Presenting Author: Provide name, address and phone number. List presenting author first and underline within the author(s) listing in the abstract block.

☐ 3. All information must fit within the rectangular blue borders of the Abstract Reproduction Form.

☐ 4. Type single spaced. Text may be a single paragraph leaving NO top or left margin within the blue box. If the text is more than one paragraph, start each paragraph with a three space indentation.

SUBMISSION INSTRUCTIONS

The following items must be included in the packet for review. Failure to enclose all items or to mail the package by the mailing deadline will lead to rejection.

1. Abstract Packets must be cancelled by an approved postal carrier NO LATER THAN DECEMBER 16, 1991.

2. Enclose a self-addressed postcard (no smaller than 3½" × 5"). The abstract title and presenting author’s name should appear on the reverse side of the card. This card will be returned to the addressee as acknowledgment of receipt. The temporary number assigned to the paper will be noted on the card.

3. Enclose the original and four (4) clear, legible copies of the completed Abstract Reproduction Form.

4. Mail the UNFOLDED original Abstract Reproduction Form, four (4) copies and the self-addressed postcard to:

1992 Abstracts
AACC Meeting Department
2029 K Street, N.W., Suite 700
Washington, D.C. 20006 USA

DEADLINE:

The Abstract Package must be cancelled by an approved postal carrier no later than December 16, 1991.

ACKNOWLEDGMENT AND NOTIFICATION

1. Upon receipt of your abstract packet the AACC Meeting Department will return the self-addressed postcard to you. A temporary number will be assigned each paper; use it when making inquiries regarding your submitted paper.

2. In April, the presenting author indicated on the Abstract Reproduction Form will receive notification of paper acceptance or rejection.

3. The presenting author of an accepted paper will receive information regarding the date and time of presentation and guidelines on how to prepare the poster.

4. If you have any technical questions about your abstract, please contact the Chairman of the Contributed Papers Committee, Daniel A. Nealon, Ph.D., 716-588-7889.

5. Other questions regarding your abstract should be directed to the AACC Meeting Department, 2029 K Street, NW, Suite 700, Washington, DC 20006 USA. In the USA: 800-892-1400, Outside USA: 202-857-0717, TELEX: 251925 AACCUR, FAX: 202-887-5093.

REGISTRATION

1. Registration materials will be available in April 1992.

2. Anyone presenting a poster is required to register for the meeting and pay the appropriate fee.

3. All AACC Members will receive registration materials. Others may obtain the registration materials by contacting the AACC Meeting Department, 2029 K Street, NW, Suite 700, Washington, DC 20006, USA, 202-857-0717/800-892-1400; TELEX 251925 AACCUR, FAX: 202-887-5093.

ATTENTION STUDENTS SEE PAGE 12A.
DEVELOPMENT OF A CEDIA™ PHENYTOIN ASSAY AND APPLICATION TO THE HITACHI® 704, Greg Marr, Sharon Horgan, Claudia Thio, Shannon Norenberg, Faegh Davoudzadeh, William Coty and Pyare Khanna (Microgenics Corp., Concord, CA 94520)

Using the CEDIA™ technology, we have developed a homogeneous immunoassay for measurement of phenytoin levels in serum which can be used in conjunction with automated clinical analyzers. In the CEDIA™ Phenytoin method, the enzyme β-galactosidase has been split into two inactive fragments, a large fragment (EA) and a smaller polypeptide (ED), which can spontaneously recombine to form active enzyme. Phenytoin is covalently attached to each ED molecule so that binding of anti-phenytoin antibodies inhibits the reassociation of EA and ED fragments. The CEDIA™ Phenytoin Assay is performed in an analyzer such as the Hitachi® 704 as follows. Sample (4 μL) is pipetted into a reaction cuvette, followed by 200 μL of Reagent 1 containing substrate and a preformed complex of anti-phenytoin antibody and ED-phenytoin conjugate. These reactants are mixed and incubated at 37°C for 5 min, and then 200 μL of Reagent 2 containing EA is added, and the incubation is continued at 37°C. Phenytoin present in the sample induces dissociation of the ED-antibody complex during its first step; the ED released is then free to combine with EA to form active β-galactosidase during the second incubation. The amount of β-galactosidase formed, which is linearly proportional to the phenytoin concentration in the sample, is determined as the rate of substrate hydrolysis measured at 415 nm during the time interval of 4 to 5 min after EA addition. The concentration of phenytoin in unknown samples is calculated automatically by comparison of the sample rates with the rates obtained with 0 and 40 μg/mL phenytoin Calibrators. Using this assay method, the following results were obtained: % assay precision (n = 20): low control—4.35 ± 0.11 μg/mL (2.6% CV; midlevel control—14.4 ± 0.1 μg/mL (0.7% CV); high control—24.5 ± 0.14 μg/mL (0.6% CV); Sensitivity (least detectable dose; 2σ) was 0.1 μg/mL. Linearity and recovery studies produced results within ± 10% of the expected concentration. Patient correlation to reference methods (commercially-available homogeneous phenytoin EIA and fluorescent polarization [FP] methods) resulted in the following least-squares regression equations: CEDIA = 0.92·EIA - 0.9 μg/mL (r = 0.997; S.E.E. = 0.9 μg/mL; n = 58); CEDIA = 0.95·FP - 2.2 μg/mL (r = 0.995; S.E.E. = 1.1 μg/mL; n = 58). Interference studies indicate negligible effect (< 10% error at 10 μg phenytoin/mL) at concentrations of ≤ 400 mg hemoglobin/dL, ≤ 1000 mg triglycerides/dL and ≤ 20 mg bilirubin/mL. Cross-reactivity to phenytoin metabolites and major anti-epileptic drugs was ≤ 1%. Preliminary results indicate that the CEDIA™ Phenytoin Assay can be adapted to other clinical analyzers, including the COBAS® BIO. Thus the CEDIA™ Phenytoin Assay is a rapid, simple and effective method for the fully-automated measurement of phenytoin concentration in human serum.
IF YOU ARE A STUDENT . . .

AND WISH TO ENTER THE STUDENT POSTER CONTEST,

AND/OR

APPLY FOR A STUDENT TRAVEL GRANT, SEE PAGE 12A.

1992 National Meeting of the
American Association for Clinical Chemistry
July 19–23, 1992
McCormick Place
Chicago, IL

Official Registration forms will be sent to all AACC members. All non-members wishing to attend the meeting must request meeting registration forms from

AACC Meeting Department
2029 K Street, N.W., Suite 700
Washington, D.C. 20006 USA

Program and Registration Materials will be available in April of 1992

CHECK LIST . . . . Have You??

☐ Filled in Topic Area?
☐ Completed Presenting Author Information at top of form?
☐ Listed Presenting Author 1st and underlined name in block in Abstract?
☐ Enclosed four (4) copies together with original?
☐ Enclosed self-addressed postcard with title and presenting author’s name and address?
☐ Supplied sufficient postage for first class mail?
Abstract Form

PRESENTING AUTHOR

Name _______________________________  Temp. # ______________
Business Address _____________________  Perm. # ______________  Notes __________________

Telephone __________________________  TOPIC AREA NUMBER
(See list of topics) ______________

Return this form and four copies along with self-addressed postcard; cancelled by an approved postal carrier no later than December 16, 1991 to:

1992 ABSTRACTS
AACC Office
2029 K Street, N.W., Suite 700
Washington, D.C. 20006 USA

□ Check here if entering Student Poster Contest. (See instruction on page 12A).

Signature ___________________________
Presenting Author
LIST OF TOPIC AREAS

Choose one of the topic areas listed below and indicate that choice on the abstract submission form by printing the topic number in the space provided on the abstract form.

<table>
<thead>
<tr>
<th>Topic #</th>
<th>Topic Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Animal clinical chemistry</td>
</tr>
<tr>
<td>02</td>
<td>Electrolytes/blood gases/metabolites</td>
</tr>
<tr>
<td>03</td>
<td>Immunology</td>
</tr>
<tr>
<td>04</td>
<td>Lipids/Lipoproteins</td>
</tr>
<tr>
<td>05</td>
<td>Nutrition and trace metals</td>
</tr>
<tr>
<td>06</td>
<td>Pediatric clinical chemistry/microchemistry</td>
</tr>
<tr>
<td>07</td>
<td>TDM/Toxicology/Drugs of Abuse</td>
</tr>
<tr>
<td>08</td>
<td>Computer applications/laboratory information systems</td>
</tr>
<tr>
<td>09</td>
<td>Instrument and product evaluation</td>
</tr>
<tr>
<td>10</td>
<td>Factors affecting test results/interferences</td>
</tr>
<tr>
<td>11</td>
<td>Enzymes/isoenzymes</td>
</tr>
<tr>
<td>12</td>
<td>Endocrinology/hormones</td>
</tr>
<tr>
<td>13</td>
<td>Proteins</td>
</tr>
<tr>
<td>14</td>
<td>Hemoglobin/coagulation/fibrinolysis</td>
</tr>
<tr>
<td>15</td>
<td>Immunoassays</td>
</tr>
<tr>
<td>16</td>
<td>Molecular biology/genetic probes</td>
</tr>
<tr>
<td>17</td>
<td>Animal and clinical studies</td>
</tr>
<tr>
<td>18</td>
<td>Cancer and tumor markers</td>
</tr>
<tr>
<td>19</td>
<td>Management</td>
</tr>
<tr>
<td>20</td>
<td>Quality assurance</td>
</tr>
</tbody>
</table>
Abstract Form

PRESENTING AUTHOR

Name ___________________________________________
Business Address __________________________________
Telephone _________________________________________

TEMP. # __________
Perm. # __________
Notes ____________________________

TOPIC AREA NUMBER
(See list of topics) ______

Return this form and four copies along with self- addressed postcard; cancelled by an approved postal carrier no later than December 16, 1991 to:

1992 ABSTRACTS
AACC Office
2029 K Street, N.W., Suite 700
Washington, D.C. 20006 USA

DO NOT FOLD THIS FORM

☐ Check here if entering Student Poster Contest. (See instruction on page 12A).

Signature ________________________________
Presenting Author
LIST OF TOPIC AREAS

Choose one of the topic areas listed below and indicate that choice on the abstract submission form by printing the topic number in the space provided on the abstract form.

<table>
<thead>
<tr>
<th>Topic #</th>
<th>Topic Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Animal clinical chemistry</td>
</tr>
<tr>
<td>02</td>
<td>Electrolytes/blood gases/metabolites</td>
</tr>
<tr>
<td>03</td>
<td>Immunology</td>
</tr>
<tr>
<td>04</td>
<td>Lipids/Lipoproteins</td>
</tr>
<tr>
<td>05</td>
<td>Nutrition and trace metals</td>
</tr>
<tr>
<td>06</td>
<td>Pediatric clinical chemistry/microchemistry</td>
</tr>
<tr>
<td>07</td>
<td>TDM/Toxicology/Drugs of Abuse</td>
</tr>
<tr>
<td>08</td>
<td>Computer applications/laboratory information systems</td>
</tr>
<tr>
<td>09</td>
<td>Instrument and product evaluation</td>
</tr>
<tr>
<td>10</td>
<td>Factors affecting test results/interferences</td>
</tr>
<tr>
<td>11</td>
<td>Enzymes/isoenzymes</td>
</tr>
<tr>
<td>12</td>
<td>Endocrinology/hormones</td>
</tr>
<tr>
<td>13</td>
<td>Proteins</td>
</tr>
<tr>
<td>14</td>
<td>Hemoglobin/coagulation/fibrinolysis</td>
</tr>
<tr>
<td>15</td>
<td>Immunooassays</td>
</tr>
<tr>
<td>16</td>
<td>Molecular biology/genetic probes</td>
</tr>
<tr>
<td>17</td>
<td>Animal and clinical studies</td>
</tr>
<tr>
<td>18</td>
<td>Cancer and tumor markers</td>
</tr>
<tr>
<td>19</td>
<td>Management</td>
</tr>
<tr>
<td>20</td>
<td>Quality assurance</td>
</tr>
</tbody>
</table>